RELATIVE CONTRIBUTIONS OF APOLIPOPROTEIN(A) AND APOLIPOPROTEIN-B TO THE DEVELOPMENT OF FATTY LESIONS IN THE PROXIMAL AORTA OF MICE

被引:40
作者
MANCINI, FP
NEWLAND, DL
MOOSER, V
MURATA, J
MARCOVINA, S
YOUNG, SG
HAMMER, RE
SANAN, DA
HOBBS, HH
机构
[1] UNIV TEXAS,SW MED CTR,DEPT MOLEC GENET,DALLAS,TX 75235
[2] UNIV TEXAS,SW MED CTR,DEPT INTERNAL MED,DALLAS,TX 75235
[3] UNIV TEXAS,SW MED CTR,HOWARD HUGHES MED CTR,DALLAS,TX 75235
[4] UNIV TEXAS,SW MED CTR,DEPT BIOCHEM,DALLAS,TX 75235
[5] UNIV CALIF SAN FRANCISCO,GLADSTONE INST CARDIOVASC DIS,SAN FRANCISCO,CA
[6] WASHINGTON UNIV,NW LIPID RES LAB,SEATTLE,WA
关键词
APO(A); LIPOPROTEIN(A); TRANSGENIC MICE; ATHEROSCLEROSIS;
D O I
10.1161/01.ATV.15.11.1911
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Transgenic mice expressing transgenes for both human apolipoprotein B-100 (h-apoB) and apolipoprotein(a) [apo(a)] were fed a high-fat, atherogenic diet for 14 weeks to examine the effect of lipoprotein(a) [Lp(a)] on the development of aortic fatty lesions. The extent of lesions in the proximal region of the aorta of Lp(a) mice was measured by use of a computer-assisted image analysis of 20 sections per animal and compared with that of nontransgenic mice as well as mice expressing either the apo(a) or h-apoB transgene. The control (n = 23) and apo(a) (n = 22) transgenic mice had very small mean lesion areas (607 versus 128 mu m(2) per section). The h-apoB-expressing mice (n = 20) had significantly higher mean lesion areas (3288 mu m(2) per section) than either the control or apo(a) transgenic animals. Coexpression of apo(a) and h-apoB transgenes resulted in only a modest increase in lesion area (4678 mu m(2) per section, n = 19). Thus, the expression of human apo(a) in C57BL/6/SJL hybrid mice fed an atherogenic diet failed to significantly potentiate the development of aortic fatty lesions in the absence or presence of high levels of h-apoB.
引用
收藏
页码:1911 / 1916
页数:6
相关论文
共 29 条
[11]  
LAPLAUD PM, 1988, J LIPID RES, V29, P1157
[12]   ATHEROGENESIS IN TRANSGENIC MICE EXPRESSING HUMAN APOLIPOPROTEIN(A) [J].
LAWN, RM ;
WADE, DP ;
HAMMER, RE ;
CHIESA, G ;
VERSTUYFT, JG ;
RUBIN, EM .
NATURE, 1992, 360 (6405) :670-672
[13]  
LEBOEUF RC, 1994, J LIPID RES, V35, P121
[14]   TRANSGENIC MICE EXPRESSING HIGH PLASMA-CONCENTRATIONS OF HUMAN APOLIPOPROTEIN B100 AND LIPOPROTEIN(A) [J].
LINTON, MF ;
FARESE, RV ;
CHIESA, G ;
GRASS, DS ;
CHIN, P ;
HAMMER, RE ;
HOBBS, HH ;
YOUNG, SG .
JOURNAL OF CLINICAL INVESTIGATION, 1993, 92 (06) :3029-3037
[15]   PREVENTION OF ATHEROSCLEROSIS IN APOLIPOPROTEIN E-DEFICIENT MICE BY BONE-MARROW TRANSPLANTATION [J].
LINTON, MF ;
ATKINSON, JB ;
FAZIO, S .
SCIENCE, 1995, 267 (5200) :1034-1037
[16]   LIPOPROTEIN(A) AND ATHEROGENESIS [J].
LIU, AC ;
LAWN, RM .
TRENDS IN CARDIOVASCULAR MEDICINE, 1994, 4 (01) :40-44
[17]  
LIU AC, 1994, J LIPID RES, V35, P2263
[18]   LIPOPROTEIN(A) IN NONHUMAN-PRIMATES - PRESENCE AND CHARACTERISTICS OF LP(A) IMMUNOREACTIVE MATERIALS USING ANTI-HUMAN LP(A) SERUM [J].
MAKINO, K ;
ABE, A ;
MAEDA, S ;
NOMA, A ;
KAWADE, M ;
TAKENAKA, O .
ATHEROSCLEROSIS, 1989, 78 (01) :81-85
[19]   LIPOPROTEIN[A] CONCENTRATIONS AND APOLIPOPROTEIN[A] PHENOTYPES IN CAUCASIANS AND AFRICAN-AMERICANS - THE CARDIA STUDY [J].
MARCOVINA, SM ;
ALBERS, JJ ;
JACOBS, DR ;
PERKINS, LL ;
LEWIS, CE ;
HOWARD, BV ;
SAVAGE, P .
ARTERIOSCLEROSIS AND THROMBOSIS, 1993, 13 (07) :1037-1045
[20]  
MARCOVINA SM, 1995, CLIN CHEM, V41, P246